WO2016170285A1 - Procédé de préparation d'un échantillon de microbiote fécal - Google Patents
Procédé de préparation d'un échantillon de microbiote fécal Download PDFInfo
- Publication number
- WO2016170285A1 WO2016170285A1 PCT/FR2016/050958 FR2016050958W WO2016170285A1 WO 2016170285 A1 WO2016170285 A1 WO 2016170285A1 FR 2016050958 W FR2016050958 W FR 2016050958W WO 2016170285 A1 WO2016170285 A1 WO 2016170285A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- microbiota
- cryoprotectant
- donor subject
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Definitions
- the present invention relates to a method for preparing a faecal microbiota sample.
- the invention also relates to the use of said sample in the transplantation of fecal microbiota, preferably for treating intestinal dysbiosis, particularly Clostridium difficile infections.
- the human intestinal microbiota is the set of micro-organisms (bacteria, yeasts and fungi) found in the human gastrointestinal system (stomach, intestine and colon). Microbial diversity is currently estimated at about 10 bacterial species making up the dominant intestinal microbiota of an adult, with an abundance of 10 14 bacteria, representing a bacterial metagenome of 200,000 to 800,000 genes in each individual, ie 10 to 50 times the number of genes in the human genome.
- the human intestinal microbiota is a very diverse ecosystem, complex and specific to each individual.
- microbiota It is essential for the health of an individual to maintain a stable microbiota that is both able to return to its original state after a change and resistant to invasion. Maintaining a great diversity of the microbiota promotes its stability. However, some pathologies or treatments unbalance the microbiota: antibiotics, for example, as well as diseases with an inflammatory component, such as inflammatory bowel disease (IBD), can limit the diversity of the microbiota in the intestine.
- IBD inflammatory bowel disease
- Antibiotic treatments result in an alteration of the microbiota, which can promote the proliferation of pathogenic organisms such as Clostridium difficile.
- Clostridium difficile infections are responsible for nosocomial diarrhea; this bacterium is resistant to conventional antibiotics (broad spectrum, such as vancomycin or metronidazole).
- the transplantation of fecal microbiota is considered and tested. It consists of introducing the stool of a healthy donor into the gastrointestinal tract of a recipient patient to rebalance the altered intestinal microbiota of the host.
- This fecal microbiota transplantation can be allogeneic (that is, from a healthy individual donor to a patient) or autologous (that is, from an individual to himself).
- Allogeneic that is, from a healthy individual donor to a patient
- autologous that is, from an individual to himself.
- the current transplantation method is empirical and takes no special precautions to best preserve the viability of anaerobic bacteria, major components of the gut microbiota.
- the efficiency of fecal microbiota transplantation is variable, and may require more than one cure.
- allogeneic transplantation requires testing the donor's faeces to ensure that no pathogenic germ will be transplanted to the recipient, or will pose a risk to personnel handling it during the operation.
- the present invention makes it possible to meet these needs.
- the present invention thus relates to a method for preparing a faecal microbiota sample from a donor subject, comprising the steps of:
- steps b) to e) being performed anaerobically.
- Such a fecal microbiota transplantation method is indeed easy to implement, and its effectiveness can be estimated by comparing the microbial population obtained after the process, compared to the initial sample. Different indices can be used to evaluate this effectiveness, and the following results could be obtained:
- the present invention also relates to the use of a sample of fecal microbiota of a donor subject that can be obtained by the method according to the invention, in the thawed state, in the transplantation of autologous or allogeneic fecal microbiota. .
- the present invention also relates to the use of a fecal microbiota sample of a donor subject that can be obtained by the process according to the invention, in the thawed state, for treating intestinal dysbiosis, and in particular the Clostridium difficile infections, dysbiosis induced by medicinal treatments, by physical treatments (radiation in particular), by surgical interventions (intestinal in particular), or by nutritional contributions.
- the present invention also relates to the use of a sample of fecal microbiota of a donor subject that can be obtained by the method according to the invention, in the thawed state, for treating a pathology selected from inflammatory bowel disease (IBD), intestinal functional disorders, obesity, metabolic diseases (type 2 diabetes, metabolic syndrome in particular) and autoimmune diseases (type 1 diabetes in particular), allergies, liver diseases (steatosis, cirrhosis in particular), certain neurological diseases (particularly autism) ) and some cancers (colorectal cancer in particular).
- IBD inflammatory bowel disease
- intestinal functional disorders e.g., obesity
- metabolic diseases type 2 diabetes, metabolic syndrome in particular
- autoimmune diseases type 1 diabetes in particular
- allergies steatosis, cirrhosis in particular
- certain neurological diseases particularly autism
- colonal cancer colonal cancer in particular
- sustained imbalance of the intestinal microbiota is meant any loss of beneficial microorganisms, and / or any loss of microorganism diversity, and / or any expansion or development of aggressive microorganisms among commensals (pathobionts), and / or or any proliferation of pathogenic micro-organisms (especially C. difficile).
- Any sustained alteration of the human intestinal microbiota can indeed cause a pathological state.
- the reduction of diversity within the microbiota is characteristic of diseases associated with dysbiosis (obesity, Crohn's disease, diabetes or allergy) (Sansonetti, Collège de France, January 22, 2014).
- the pathology to be treated is intestinal dysbiosis.
- IBD Inflammatory chronic diseases of the intestine
- Functional bowel disorders include irritable bowel syndrome, spasmodic colitis.
- the method for preparing a sample of fecal microbiota of a donor subject thus comprises a step a) of sampling at least one sample of faecal microbiota from the donor subject.
- the method according to the invention comprises a step a) of sampling at least one stool sample, comprising the fecal microbiota, from the donor subject.
- the donor subject is a healthy human subject.
- healthy subject we mean a subject not suffering from an imbalance of the intestinal microbiota or a pathology diagnosed / recognized by the medical profession.
- the stool sample has a mass of at least 20 g.
- step b) the sample obtained in a) is placed in an oxygen-tight collection device: this is step b).
- the airtight collection device is in a form of the type comprising:
- a container comprising a body that has an interior space adapted to receive the fecal microbiota sample from the donor subject, and a neck that delimits an access opening to the interior space of the body, and
- a cover adapted to be removably and sealingly mounted on the neck of the container so as to close the access opening of the neck and to close the interior space of the body
- the body of the container consists of a flexible bag, and wherein at least one of the container and the lid is provided with a discharge member adapted to discharge at least a portion of the gases contained in the interior space of the container body.
- the device discharge member includes a passageway through one of the container and the lid, and a closure member of the passage to prevent external fluids from entering the interior space of the body. of the container.
- the device discharge member further comprises a microporous filtration membrane disposed in the passage.
- the airtight collection device is in a form of the type comprising: a container comprising a body that has an interior space adapted to receive the fecal microbiota sample from the donor subject, and a neck that delimits an access opening to the interior space of the body, and
- a cover adapted to be removably and sealingly mounted on the neck of the container so as to close the access opening of the neck and to close the interior space of the body
- interior space of the container body optionally comprises an oxygen neutralizing chemical device.
- the airtight collection device is used for steps a) and b): the sampling of the sample of step a) is carried out directly in said device, in particular in the container, and the closure of the device, in particular by means of the lid, places the sample in an oxygen-free atmosphere (step b).
- steps b) to e) are carried out under an oxygen-free atmosphere.
- anaerobiosis the viability of the bacteria constituting the fecal microbiota present in the sample is thus preserved.
- the device used in step b), mentioned above makes it possible to perform all the steps b) to e) under anaerobic conditions.
- the sample (obtained in a) may optionally be incubated at a temperature of between 33 ° C. and 40 ° C. for a maximum duration of 75 hours.
- this incubation step is carried out at a temperature between 35 ° C and 38 ° C for a period of between 24 and 73 hours.
- this step is done at a temperature of about 37 ° C for 72h.
- the sample may, optionally, be incubated at a temperature between 2 ° C and 10 ° C for a maximum of 75h.
- this incubation step is carried out at a temperature between 4 ° C and 8 ° C, for a period of between 24 and 72 hours.
- a visual check can be made to evaluate the quality of the sample obtained at this stage of the process. If this check is compliant, optionally, a transport step can take place. This transport step makes it possible to repatriate the sample from the sampling site to the laboratory, for further processing and analysis. The aforementioned visual inspection can also be carried out after the transport.
- the sample placed in the collection device of step b) undergoes a transport step before step c).
- the sample placed in the collection device of step b) is incubated at a temperature of between 33 ° C. and 40 ° C., preferably between 35 ° C. and 38 ° C., for a maximum duration of 75h, preferably between 24h and 73h, between steps b) and c).
- the incubation takes place before and during the transport step.
- step c) this step comprises mixing the sample obtained in b) with at least one aqueous saline solution comprising at least one cryoprotectant and / or a filler.
- step c) obviously comprises mixing the sample obtained in b), after transport and / or incubation, with at least one aqueous solution saline comprising at least one cryoprotectant and / or a filler.
- the aqueous salt solution according to the invention comprises water and physiologically acceptable salts.
- the salts are calcium, sodium, potassium or magnesium salts, with chloride, gluconate, acetate or hydrogencarbonate ions.
- the aqueous saline solution according to the invention may also optionally comprise at least one antioxidant.
- the antioxidant is especially chosen from ascorbic acid and its salts (ascorbate), tocopherols (especially -tocopherol), cysteine and its salified forms (hydrochloride in particular) and their mixtures.
- the aqueous saline solution according to the invention comprises:
- At least one salt selected from sodium chloride, calcium chloride, magnesium chloride, potassium chloride, sodium gluconate and sodium acetate, and optionally at least one antioxidant, preferably chosen from sodium L-ascorbate, tocopherols, L-cysteine hydrochloride monohydrate and their mixtures.
- the salt is present in the aqueous saline solution in a concentration of between 5 and 20 g / l, preferably between 7 and 10 g / l.
- antioxidant is present in the aqueous saline solution in an amount of between 0.3 and 1% by weight relative to the total volume of solution, preferably in an amount of between 0.4 and 0.6% by weight relative to the total volume of solution.
- the antioxidant is a mixture of sodium L-ascorbate and L-cysteine hydrochloride monohydrate
- the sodium L-ascorbate is present in an amount of between 0.4 and 0.6% by weight relative to the total volume of solution
- the L-cysteine hydrochloride monohydrate is present in an amount of between 0.01 and 0.1% by weight relative to the total volume of solution.
- the aqueous saline solution according to the invention also comprises at least one cryoprotectant.
- a cryoprotectant is a substance used to protect the sample from damage caused by freezing, especially due to the formation of ice crystals.
- the cryoprotectant is chosen from polyols, di-pentasaccharides (L-disaccharides, trisaccharides, quadrisaccharides and pentasaccharides), DMSO and mixtures thereof.
- the cryoprotectant is chosen from polyols, tri- and disaccharides, DMSO and mixtures thereof. More preferably, the cryoprotectant present in the aqueous saline solution is a disaccharide or a trisaccharide.
- glycerol mannitol, sorbitol, but also propylene glycol or ethylene glycol may be found.
- di-pentasaccharides that may be used, mention may be made of dimers, trimers, quadrimers and pentamers of identical or different units, said units being chosen from glucose, fructose, galactose, fucose and N-acetylneuraminic acid.
- disaccharides that can be used are, in particular, trehalose or one of its analogues, or sucrose.
- DMSO dimethylsulfoxide
- cryoprotectants can be used alone or as a mixture.
- the total amount of cryoprotectant present in the aqueous saline solution is between 3 and 30% by weight relative to the total volume of solution, preferably between 4% and 20% by weight relative to the total volume of solution.
- the cryoprotectant is chosen from glycerol, mannitol, sorbitol, DMSO, propylene glycol, ethylene glycol, trehalose and its analogues, sucrose, galactose-lactose and their mixtures. More preferably, the cryoprotectant is galactose-lactose or trehalose.
- the aqueous saline solution according to the invention comprises at least one filler.
- the bulking agent is preferably selected from partial hydrolysates of starch or starch.
- Partial hydrolysates of starch, in particular wheat or maize, as well as partial hydrolysates of starch, for example of potato, comprise a large quantity of maltodextrins.
- Maltodextrins are the result of the partial hydrolysis of starch or starch, and consist of various sugars (glucose, maltose, maltotriose, oligo- and polysaccharides), the proportions of which vary according to the degree of hydrolysis.
- the bulking agent present in the aqueous saline solution is a mixture of maltodextrins, wherein the amount of maltodextrins is between 4 and 20% by weight relative to the total volume of solution.
- the aqueous saline solution according to the invention comprises at the same time:
- cryoprotectant as described above, i.e. selected from polyols, di-pentasaccharides (i.e., disaccharides, trisaccharides, quadrisaccharides and pentasaccharides), DMSO and mixtures thereof, and
- At least one filler as described above i.e. selected from the partial hydrolysates of starch or starch, preferably the filler consists of maltodextrins.
- the amount of cryoprotectant is between 3 and 30% by weight relative to the total volume of solution, preferably between 4% and 20% by weight. in relation to the total volume of solution; and the amount of the filler, preferably maltodextrins, is from 4 to 20% by weight based on the total volume of solution.
- Step c) of mixing the sample obtained in b) with at least one aqueous saline solution comprising at least one cryoprotectant may in particular be carried out by kneading, in order to obtain a homogeneous mixture.
- the sample obtained in b) is mixed with said aqueous saline solution in a weight / volume ratio of between 0.5 weight: 10 volumes and 2 weight: 2 volumes.
- a sample weight / volume ratio: solution equal to 0.5 weight: 10 volumes means that the sample is mixed with 0.5 weight (for example 0.5 g) for 10 volumes of solution (for example 10 ml).
- the weight / volume sample: solution is equal to 1 sample weight for 4 volumes of solution (1 weight: 4 volumes).
- Step d) comprises the filtration of the mixture obtained in c), in particular by a filter comprising pores with a diameter of less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm. Such a filtration allows the retention of coarse particles, and the recovery of the bacteria of interest (constitutive of the fecal microbiota) in the filtrate.
- step e the freezing (and therefore storage) temperature is between -60 ° C and -90 ° C; more preferably it is about -80 ° C or about -65 ° C.
- the mixture can be aliquoted beforehand, to ensure specimens of constant volume.
- the aliquoting is performed to obtain specimens of volume equal to 50 ml, 100 ml, 150 ml, or 200 ml.
- the aliquoting is performed to obtain specimens of volume equal to 100 ml.
- This freezing and storage step makes it possible to keep the treated samples for a period of at least 2 months.
- the samples thus stored also have good quality, even after thawing.
- the process according to the invention comprises a step f) of thawing the frozen sample obtained in e), under anaerobic conditions, to room temperature.
- This f) defrosting step may be carried out by placing the frozen sample in a water bath at a temperature of between 35 ° C. and 40 ° C., for example 37 ° C., for a period of a few minutes (typically from 2 to 10 minutes).
- the thawing step f) can also be carried out by placing the frozen sample at a temperature of between 2 ° C. and 10 ° C., for example between 4 ° C. and 8 ° C., for a period of 10 to 20 hours. .
- the thus thawed sample at room temperature can then be administered to the recipient patient.
- the recipient patient may be different from the donor subject, and the transplant is then allogenic.
- the recipient patient may also be identical to the donor subject, and the transplant is then autologous; this type of transplantation can take place when the subject, while healthy, gives a sample before the alteration of its microbiota.
- the sample is then frozen according to the steps described in the present application, and then transplanted to the same subject (recipient patient) if it has in particular a Clostridium difficile infection.
- Autologous fecal microbiota transplantation has the advantage of avoiding transmission of pathogen from another donor.
- the present invention also relates to a fecal microbiota sample of a donor subject that can be obtained by the method according to the invention, for its use in the transplantation of autologous or allogenic fecal microbiota.
- the present invention also relates to a faecal microbiota sample of a donor subject obtainable by the process according to the invention, for its use for treating Clostridium difficile infections.
- the present invention also relates to a fecal microbiota sample of a donor subject susceptible to be obtained by the method according to the invention, for its use for treating a pathology selected from inflammatory bowel disease (IBD), intestinal functional disorders, obesity, metabolic diseases and autoimmune diseases. immune, allergies, neurological diseases and cancers.
- IBD inflammatory bowel disease
- Figure 3 Spearman correlations at the bacterial genus level for the different diluents tested after one week of storage, compared to the "fresh stool" control
- Figure 4 Kinetics of colonization of Bacteroides and Faecalibacterium populations in mouse feces Example 1 Preparation of a Fecal Microbiota Sample of a Donor Subject According to the Invention
- the stools are homogenized for 5 minutes in anaerobic atmosphere, by manual mixing in the collection bag (step b) of the process).
- Small aliquots 150-200 mg) of crude fecal matter (SB for Brute Saddle) are retained for profiling of 16S rDNA and 16S rRNA of raw faeces.
- An aliquot (1 g) is diluted in enriched cold heart brain broth, centrifuged at 220,000xg, at 4 ° C for 1h, and the supernatant is fractionated into 1ml aliquots for metabolomic profiling of raw faecal water.
- Aliquots for DNA, RNA and metabolomic profiling are stored at -80 ° C.
- a third aliquot (0.4 g) is diluted in 1.6 ml of the culture broth and used to inoculate 3 Kimax culture tubes (0.5 ml of inoculum per 9.5 ml of broth, extemporaneously enriched in L-ascorbate of sodium and L-cysteine hydrochloride monohydrate at a final concentration of 0.5% [w / v] and 0.05% [w / v], respectively) for the baseline activity test.
- Eight stool fractions are then transferred to Stomacher filter bags: 4 bags for conditioning in the four diluents under anaerobic conditions, and four bags for packaging in the same four diluents under aerobic conditions.
- MDX 15 - MDX (maltodextrins) 15% (w / v) + TR (trehalose) 5% (w / v) in 9g / L saline solution (identified as "MDX 15")
- the MDX and TRI 5 preparations carried out under anaerobic atmosphere are further supplemented by the two reducing agents, sodium L-ascorbate and L-cysteine monohydrate hydrochloride, at a final concentration of 0.5% (w / v) and 0.1 % (w / v), respectively.
- Resuspension is provided by manual mixing for 5 minutes through the bag. This mixture provides filtration at the same time, through a gauze (0.5 mm holes) present in the bag (step d) of the process).
- CryoMACS bags are thawed for 3 consecutive days at a rate of one bag per person per day. Thawing is performed according to two different protocols (step f) of the process):
- the samples are cultured in enriched brain heart broth, and the metabolic activity is evaluated. Aliquots of thawed filtrates before culture (thawed non-cultured filtrates) are also conserved for 16S rDNA, 16S rRNA, and metabolomic profiling.
- a sample is collected and used to seed triplicate culture tubes each containing 9.5 ml of enriched brain-core broth.
- the culture tubes had already been reduced in the anaerobic chamber to remove any dissolved oxygen and allow the growth of strict anaerobic bacteria.
- the triplicate cultures are harvested, pooled in Falcon50 tubes, and centrifuged for 30 min at 5000 x g, 4 ° C. The supernatant is further ultracentrifuged for 1 hour at 220,000 xg, 4 ° C for metabolomic profiling (1 ml fraction supernatant stored at -80 ° C), while the wet 5,000 xg pellet is divided into three parts. Equal fractions in Sarstedt tubes for 16S rDNA and 16S rRNA, all aliquots being stored at -80 ° C until analyzes.
- Metabolomic analyzes are then performed to obtain LC-MS (Q-Exactive Thermofisher Scientific) profiles in positive and negative ionization modes.
- the total DNA is extracted. It is then controlled and sequenced by pyrosequencing. Transcriptomic profiles
- RNA is extracted using the following method: briefly, the bacteria are lysed by chemical and mechanical treatment; then the lysates are precipitated and centrifuged; finally the RNA is isolated and purified on minicolumns using the kit High Pure Isolation Kit (Roche). Their integrity is evaluated and they are then subjected to RT-PCR.
- the cDNAs are sequenced by pyrosequencing and then subjected to the same analysis as for the DNA.
- the major discriminating factor is the subject. This was expected since the host specificity of the microbial flora is well established. This means that whatever the stool conditioning effect, it will respect the host specificity. The comparisons made will therefore be reliable and the behaviors preserved for different individuals will be more significant.
- Figure 1 shows the Pearson correlations between phylo-transcriptomic profiles obtained from the bacterial family distribution in the total RNA of the different fractions prepared.
- the reference is the profile obtained from raw faeces (SB for 'raw stool').
- MDX15 frozen with 15% maltodextrins and 5% trehalose (MDX15" described in Example 1); or
- Samples and analyzes after 2 days, 4 days and 15 days, 2 to 3 freshly and spontaneously emitted faecal pellets are collected per animal in the morning for microbiological analysis. In addition, a sample of caecal content is collected at sacrifice at 15 days for phylogenomic and / or transcriptomic and metabolomic analysis.
- Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A, pp. 105 (43): 16731-6.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL255100A IL255100B (en) | 2015-04-24 | 2016-04-22 | A method for preparing a sample of microbiota from feces |
CN201680023630.8A CN107530280B (zh) | 2015-04-24 | 2016-04-22 | 粪便微生物群样品的制备方法 |
JP2018506488A JP6858747B2 (ja) | 2015-04-24 | 2016-04-22 | 便微生物試料を調製する方法 |
PL16723433T PL3285784T3 (pl) | 2015-04-24 | 2016-04-22 | Sposób wytwarzania próbki mikrobioty kałowej |
CA2983192A CA2983192A1 (fr) | 2015-04-24 | 2016-04-22 | Procede de preparation d'un echantillon de microbiote fecal |
ES16723433T ES2812854T3 (es) | 2015-04-24 | 2016-04-22 | Procedimiento de preparación de una muestra de microbiota fecal |
DK16723433.5T DK3285784T3 (da) | 2015-04-24 | 2016-04-22 | Fremgangsmåde til fremstilling af en prøve af fækal mikrobiota |
AU2016252209A AU2016252209B2 (en) | 2015-04-24 | 2016-04-22 | Method of preparing a faecal microbiota sample |
US15/568,838 US10980839B2 (en) | 2015-04-24 | 2016-04-22 | Method of preparing a faecal microbiota sample |
EP16723433.5A EP3285784B1 (fr) | 2015-04-24 | 2016-04-22 | Procédé de préparation d'un échantillon de microbiote fécal |
US17/167,573 US20210154239A1 (en) | 2015-04-24 | 2021-02-04 | Method of preparing a faecal microbiota sample |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1553716A FR3035328B1 (fr) | 2015-04-24 | 2015-04-24 | Procede de preparation d'un echantillon de microbiote fecal |
FR1553716 | 2015-04-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/568,838 A-371-Of-International US10980839B2 (en) | 2015-04-24 | 2016-04-22 | Method of preparing a faecal microbiota sample |
US17/167,573 Continuation US20210154239A1 (en) | 2015-04-24 | 2021-02-04 | Method of preparing a faecal microbiota sample |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016170285A1 true WO2016170285A1 (fr) | 2016-10-27 |
Family
ID=53794336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2016/050958 WO2016170285A1 (fr) | 2015-04-24 | 2016-04-22 | Procédé de préparation d'un échantillon de microbiote fécal |
Country Status (14)
Country | Link |
---|---|
US (2) | US10980839B2 (fr) |
EP (1) | EP3285784B1 (fr) |
JP (1) | JP6858747B2 (fr) |
CN (1) | CN107530280B (fr) |
AU (1) | AU2016252209B2 (fr) |
CA (1) | CA2983192A1 (fr) |
DK (1) | DK3285784T3 (fr) |
ES (1) | ES2812854T3 (fr) |
FR (1) | FR3035328B1 (fr) |
HU (1) | HUE050430T2 (fr) |
IL (1) | IL255100B (fr) |
PL (1) | PL3285784T3 (fr) |
PT (1) | PT3285784T (fr) |
WO (1) | WO2016170285A1 (fr) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017103225A1 (fr) * | 2015-12-18 | 2017-06-22 | Institut National De La Recherche Agronomique | Composition lyophilisee pour la conservation de microbiote dans son ecosysteme |
WO2018138251A1 (fr) | 2017-01-26 | 2018-08-02 | Sorbonne Universite | Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques |
US10119116B2 (en) * | 2016-07-28 | 2018-11-06 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
EP3485879A1 (fr) | 2017-11-17 | 2019-05-22 | Maat Pharma | Formulation pharmaceutique orale comprenant bactéries |
WO2019171012A1 (fr) * | 2018-03-09 | 2019-09-12 | Maat Pharma | Procédure de collecte de selles et procédé de préparation d'un échantillon pour transplantation de microbiote fécal |
EP3597202A1 (fr) | 2018-07-20 | 2020-01-22 | Maat Pharma | Composition du microbiote fécal destinée à être utilisée pour réduire l'inflammation induite par traitement |
JP2020521760A (ja) * | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
EP3895716A1 (fr) | 2020-04-17 | 2021-10-20 | Maat Pharma | Test de prédiction de performance fmt pour guider et optimiser la gestion thérapeutique de patients atteints d'une réaction du greffon contre l'hôte (gvhd) |
WO2022136694A1 (fr) | 2020-12-23 | 2022-06-30 | Maat Pharma | Procédé de multiplication d'une communauté complexe de micro-organismes |
EP4086337A1 (fr) | 2021-05-06 | 2022-11-09 | Maat Pharma | Procédé de prédiction puis de production d'un mélange d'échantillons de microbiote |
RU2816462C2 (ru) * | 2018-07-20 | 2024-03-29 | Маат Фарма | Композиция фекальной микробиоты для применения для уменьшения индуцированного лечением воспаления |
EP4369344A1 (fr) | 2022-11-08 | 2024-05-15 | Maat Pharma | Détermination d'échantillons de microbiote pour produire un produit de mélange cible et prédiction de mélanges |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010380A (zh) * | 2018-08-21 | 2018-12-18 | 卓源健康科技有限公司 | 一种粪菌移植临床治疗中的肠道菌群制剂的工艺 |
EP3979916A4 (fr) * | 2019-06-07 | 2023-06-07 | Anaerobe Systems | Formulations, dispositifs et systèmes de prélèvement microbien |
RU2745125C1 (ru) * | 2020-07-15 | 2021-03-22 | Общество с ограниченной ответственностью «Байкальский центр биомедицинских исследований» (ООО «БайкалБиоМед») | Устройство и способ подготовки в анаэробных условиях донорской фекальной микробиоты к трансплантации |
CN112226369A (zh) * | 2020-10-23 | 2021-01-15 | 重庆浦洛通基因医学研究院有限公司 | 一种肠道菌群保存液及制备方法 |
RU2761047C1 (ru) * | 2021-03-10 | 2021-12-02 | Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" | Устройство для подготовки донорского фекального материала к трансплантации |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012122478A1 (fr) * | 2011-03-09 | 2012-09-13 | Regents Of The University Of Minnesota | Compositions et procédés de transplantation du microbiote du côlon |
US20140363398A1 (en) * | 2013-06-05 | 2014-12-11 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
US20150037285A1 (en) * | 2013-07-03 | 2015-02-05 | New York University | Methods for efficient transfer of viable and bioactive microbiota |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
KR20100088894A (ko) * | 2009-02-02 | 2010-08-11 | 에이엠바이오 (주) | 멤브레인 생물반응기를 이용한 고농도 유산균의 생산방법 및 유산균 동결건조 분말의 제조방법 |
JP5897459B2 (ja) * | 2009-04-30 | 2016-03-30 | イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV | 乳酸菌のフリーズドライのための凍結保護剤 |
CN106987525B (zh) * | 2009-05-26 | 2020-10-27 | 先进生物营养公司 | 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法 |
US7888062B1 (en) * | 2010-02-01 | 2011-02-15 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
EP2552321B1 (fr) | 2010-04-02 | 2014-03-12 | Antonius Henricus Petrus Bosch | Dispositif auxiliaire destiné à recevoir des matières fécales |
SG187713A1 (en) | 2010-08-04 | 2013-03-28 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
WO2014152484A1 (fr) * | 2013-03-14 | 2014-09-25 | Regents Of The University Of Minnesota | Microbiote fécal lyophilisé à utiliser dans la transplantation microbienne fécale |
CN103160489B (zh) * | 2011-12-12 | 2015-01-14 | 润盈生物工程(上海)有限公司 | 日化微胶囊益生菌的制备方法 |
US10093894B2 (en) * | 2012-08-20 | 2018-10-09 | Chr. Hansen A/S | Method for optimizing a process for freeze drying a bacteria-containing concentrate |
CN102827796B (zh) * | 2012-09-03 | 2013-10-30 | 江南大学 | 一种具有排镉功能的植物乳杆菌及其用途 |
BR112015012123A8 (pt) | 2012-11-26 | 2018-01-23 | Borody Thomas J | composições para a recuperação de uma microbiota fecal e métodos para produzir e usar as mesmas. |
BR112015018625A2 (pt) | 2013-02-04 | 2017-09-19 | Seres Therapeutics Inc | composições e métodos |
EP3904502A3 (fr) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions et procédés |
US20160089363A1 (en) | 2013-04-30 | 2016-03-31 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
IL281424B2 (en) | 2015-06-09 | 2023-10-01 | Rebiotix Inc | Microbiota restoration treatment preparations and production methods |
RU2018118651A (ru) | 2015-10-26 | 2019-12-04 | КРЕСТОВО ХОЛДИНГЗ ЭлЭлСи | Композиции и способы терапии, связанной с фекальной микробиотой |
-
2015
- 2015-04-24 FR FR1553716A patent/FR3035328B1/fr active Active
-
2016
- 2016-04-22 US US15/568,838 patent/US10980839B2/en active Active
- 2016-04-22 ES ES16723433T patent/ES2812854T3/es active Active
- 2016-04-22 EP EP16723433.5A patent/EP3285784B1/fr active Active
- 2016-04-22 PT PT167234335T patent/PT3285784T/pt unknown
- 2016-04-22 WO PCT/FR2016/050958 patent/WO2016170285A1/fr active Application Filing
- 2016-04-22 DK DK16723433.5T patent/DK3285784T3/da active
- 2016-04-22 HU HUE16723433A patent/HUE050430T2/hu unknown
- 2016-04-22 AU AU2016252209A patent/AU2016252209B2/en active Active
- 2016-04-22 JP JP2018506488A patent/JP6858747B2/ja active Active
- 2016-04-22 IL IL255100A patent/IL255100B/en unknown
- 2016-04-22 CN CN201680023630.8A patent/CN107530280B/zh active Active
- 2016-04-22 CA CA2983192A patent/CA2983192A1/fr active Pending
- 2016-04-22 PL PL16723433T patent/PL3285784T3/pl unknown
-
2021
- 2021-02-04 US US17/167,573 patent/US20210154239A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012122478A1 (fr) * | 2011-03-09 | 2012-09-13 | Regents Of The University Of Minnesota | Compositions et procédés de transplantation du microbiote du côlon |
US20140363398A1 (en) * | 2013-06-05 | 2014-12-11 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
US20150037285A1 (en) * | 2013-07-03 | 2015-02-05 | New York University | Methods for efficient transfer of viable and bioactive microbiota |
Non-Patent Citations (4)
Title |
---|
EVERARD, A.: "Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity", PROC NATL ACAD SCI USA, vol. 110, no. 22, 2013, pages 9066 - 71 |
HAMILTON MATTHEW J ET AL: "Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection", AMERICAN JOURNAL OF GASTROENTEROLOGY, ELSEVIER SCIENCE INC, US, vol. 107, no. 5, 1 May 2012 (2012-05-01), pages 761 - 767, XP009161359, ISSN: 0002-9270 * |
SOKOL, H.: "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", PROC NATL ACAD SCI U S A, vol. 105, no. 43, 2008, pages 16731 - 6 |
TAUXE ET AL., LAB MEDICINE, vol. 46, no. 1, 2015 |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017103225A1 (fr) * | 2015-12-18 | 2017-06-22 | Institut National De La Recherche Agronomique | Composition lyophilisee pour la conservation de microbiote dans son ecosysteme |
US11110133B2 (en) | 2015-12-18 | 2021-09-07 | Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Lyophilized composition for preserving microbiota in its ecosystem |
JP2018537504A (ja) * | 2015-12-18 | 2018-12-20 | アンスティトゥー ナショナル ドゥ ラ ルシェルシュ アグロノミーク | 生態系のままの微生物叢を保存するために凍結乾燥された組成物 |
US10119116B2 (en) * | 2016-07-28 | 2018-11-06 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
US10767157B2 (en) | 2016-07-28 | 2020-09-08 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
CN110520141A (zh) * | 2017-01-26 | 2019-11-29 | 索邦大学 | 用于治疗接受造血干细胞移植的患者的粪便微生物群 |
WO2018138251A1 (fr) | 2017-01-26 | 2018-08-02 | Sorbonne Universite | Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques |
JP2020506183A (ja) * | 2017-01-26 | 2020-02-27 | ソルボンヌ・ユニヴェルシテ | 造血幹細胞移植を受けている患者を治療するための便細菌叢 |
JP2020521760A (ja) * | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
WO2019097030A1 (fr) | 2017-11-17 | 2019-05-23 | Maat Pharma | Formulation pharmaceutique orale comprenant des bactéries |
EP3485879A1 (fr) | 2017-11-17 | 2019-05-22 | Maat Pharma | Formulation pharmaceutique orale comprenant bactéries |
KR102524970B1 (ko) * | 2018-03-09 | 2023-04-21 | 매트 파마 | 분변 미생물총 이식을 위한 대변 수집 방법 및 샘플 제조 방법 |
US11389488B2 (en) | 2018-03-09 | 2022-07-19 | Maat Pharma | Stool collection method and sample preparation method for transplanting fecal microbiota |
KR20200130367A (ko) * | 2018-03-09 | 2020-11-18 | 매트 파마 | 분변 미생물총 이식을 위한 대변 수집 방법 및 샘플 제조 방법 |
JP2021517131A (ja) * | 2018-03-09 | 2021-07-15 | マー ファルマ | 糞便回収方法及び糞便微生物叢を移植するためのサンプル調製方法 |
FR3078627A1 (fr) * | 2018-03-09 | 2019-09-13 | Maat Pharma | Procedure de collecte de selles et procede de preparation d'un echantillon pour transplantation de microbiote fecal |
JP7330998B2 (ja) | 2018-03-09 | 2023-08-22 | マー ファルマ | 糞便回収方法及び糞便微生物叢を移植するためのサンプル調製方法 |
WO2019171012A1 (fr) * | 2018-03-09 | 2019-09-12 | Maat Pharma | Procédure de collecte de selles et procédé de préparation d'un échantillon pour transplantation de microbiote fécal |
IL276969B2 (en) * | 2018-03-09 | 2024-07-01 | Maat Pharma | Stool collection method and sample preparation method for faecal microbiota transplantation |
IL276969B1 (en) * | 2018-03-09 | 2024-03-01 | Maat Pharma | Stool collection method and sample preparation method for faecal microbiota transplantation |
EP3597202A1 (fr) | 2018-07-20 | 2020-01-22 | Maat Pharma | Composition du microbiote fécal destinée à être utilisée pour réduire l'inflammation induite par traitement |
RU2816462C2 (ru) * | 2018-07-20 | 2024-03-29 | Маат Фарма | Композиция фекальной микробиоты для применения для уменьшения индуцированного лечением воспаления |
EP4389209A2 (fr) | 2018-07-20 | 2024-06-26 | Maat Pharma | Composition de microbiote fécal destinée à être utilisée dans la réduction d'une inflammation induite par un traitement |
WO2020016445A1 (fr) | 2018-07-20 | 2020-01-23 | Maat Pharma | Composition de microbiote fécal destinée à être utilisée dans la réduction d'une inflammation induite par un traitement |
US20210299188A1 (en) * | 2018-07-20 | 2021-09-30 | Maat Pharma | Fecal microbiota composition for use in reducing treatment-induced inflammation |
EP3895716A1 (fr) | 2020-04-17 | 2021-10-20 | Maat Pharma | Test de prédiction de performance fmt pour guider et optimiser la gestion thérapeutique de patients atteints d'une réaction du greffon contre l'hôte (gvhd) |
WO2021209631A1 (fr) | 2020-04-17 | 2021-10-21 | Maat Pharma | Test de prédiction de performance de fmt pour guider et optimiser la gestion thérapeutique de patients gvhd |
WO2022136694A1 (fr) | 2020-12-23 | 2022-06-30 | Maat Pharma | Procédé de multiplication d'une communauté complexe de micro-organismes |
WO2022234053A1 (fr) | 2021-05-06 | 2022-11-10 | Maat Pharma | Procédé de prédiction et de production d'un mélange d'échantillons de microbiote |
EP4086337A1 (fr) | 2021-05-06 | 2022-11-09 | Maat Pharma | Procédé de prédiction puis de production d'un mélange d'échantillons de microbiote |
EP4369344A1 (fr) | 2022-11-08 | 2024-05-15 | Maat Pharma | Détermination d'échantillons de microbiote pour produire un produit de mélange cible et prédiction de mélanges |
WO2024099981A1 (fr) | 2022-11-08 | 2024-05-16 | Maat Pharma | Détermination d'échantillons de microbiote pour produire un produit de mélange cible et prédiction de mélanges |
Also Published As
Publication number | Publication date |
---|---|
PL3285784T3 (pl) | 2020-11-16 |
JP6858747B2 (ja) | 2021-04-14 |
US10980839B2 (en) | 2021-04-20 |
FR3035328B1 (fr) | 2019-08-23 |
ES2812854T3 (es) | 2021-03-18 |
PT3285784T (pt) | 2020-08-31 |
FR3035328A1 (fr) | 2016-10-28 |
EP3285784B1 (fr) | 2020-07-08 |
US20210154239A1 (en) | 2021-05-27 |
IL255100A0 (en) | 2017-12-31 |
US20180099012A1 (en) | 2018-04-12 |
JP2018514228A (ja) | 2018-06-07 |
AU2016252209B2 (en) | 2022-03-03 |
CN107530280A (zh) | 2018-01-02 |
EP3285784A1 (fr) | 2018-02-28 |
CA2983192A1 (fr) | 2016-10-27 |
AU2016252209A1 (en) | 2017-12-07 |
IL255100B (en) | 2022-09-01 |
DK3285784T3 (da) | 2020-08-24 |
HUE050430T2 (hu) | 2020-12-28 |
CN107530280B (zh) | 2021-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3285784B1 (fr) | Procédé de préparation d'un échantillon de microbiote fécal | |
EP3389679B1 (fr) | Procede de lyophilisation d'un echantillon de microbiote fecal | |
CA3091626C (fr) | Procedure de collecte de selles et procede de preparation d'un echantillon pour transplantation de microbiote fecal | |
EP3573631B1 (fr) | Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques | |
CN110791435A (zh) | 一种低温冻存保存液 | |
Mustafa | A Study of the Symbiotic Relationship between Prausnitzn Faecalibacterum and Other Colon Species | |
EP4263801A1 (fr) | Milieu de culture, procede de fabrication et procede de culture bacterienne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16723433 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 255100 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2983192 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018506488 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15568838 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016252209 Country of ref document: AU Date of ref document: 20160422 Kind code of ref document: A |